Route-coupled pathogenicity and immunogenicity of vaccinia virus variant inoculated mice

Vaccinia virus had played a key role in the global smallpox eradication. However, in case of mass vaccination with various Vaccinia virus strains severe side effects were revealed sometimes ending up with lethal outcomes, especially in immunocompromised humans. Hence, in 1980 the World Health Organi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	S. N. Shchelkunov, A. A. Sergeev, A. S. Kabanov, S. N. Yakubitskyi, T. V. Bauer, S. A. Pyankov
Formato:	article
Lenguaje:	RU
Publicado:	Sankt-Peterburg : NIIÈM imeni Pastera 2021
Materias:	vaccinia virus attenuation infection pathogenicity immune response antibodies Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/5661108ca47949eabc4a92db7f760dab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5661108ca47949eabc4a92db7f760dab
record_format	dspace
spelling	oai:doaj.org-article:5661108ca47949eabc4a92db7f760dab2021-11-22T07:09:54ZRoute-coupled pathogenicity and immunogenicity of vaccinia virus variant inoculated mice2220-76192313-739810.15789/2220-7619-PAI-1375https://doaj.org/article/5661108ca47949eabc4a92db7f760dab2021-03-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/1375https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398Vaccinia virus had played a key role in the global smallpox eradication. However, in case of mass vaccination with various Vaccinia virus strains severe side effects were revealed sometimes ending up with lethal outcomes, especially in immunocompromised humans. Hence, in 1980 the World Health Organization recommended to cancel smallpox vaccination after declaring about smallpox eradication. Over the last 40 years, human population virtually lost immunity not only against smallpox, but also against other zoonotic orthopoxvirus infections, such as monkeypox, cowpox, buffalopox, and camelpox. All of them pose a represent increasing threat to human health and heighten a risk of emerging highly contagious viruses due to natural evolution of previous zoonotic orthopoxviruses. In order to prevent development of small outbreaks into spreading epidemics and, thus, to decrease a risk of emergence due to natural evolution of highly pathogenic for humans orthopoxviruses, efforts should be applied to develop safe new generation live vaccines based on Vaccinia virus with target virulence genes inactivation. These strains should be examined in laboratory animal models inoculated via different routes. Currently, Vaccinia virus often becomes attenuated to create live recombinant vaccines due to inserting target DNA sequences into the virus virulence genes resulting in their inactivation. Vaccinia virus strain LIVP used in the Russian Federation as smallpox vaccine as well as derivative attenuated variant LIVP-GFP created by using genetic engineering methods with inactivating its thymidine kinase gene were examined. Such viruses were intracerebrally inoculated into suckling mice at doses of 101 or 102 PFU/animal for neurovirulence assessment. Adult mice were infected intranasally, subcutaneously or intradermally at doses of 107 or 108 PFU/animal and clinical manifestations were analyzed for 14 days. On the 28th day after the onset, blood serum samples were collected from individual mice to measure virus specific antibody level by using ELISA. It was shown that recombinant Vaccinia virus strain LIVP-GFP displayed markedly lowered neurovirulence and pathogenicity for mice as compared to parental LIVP. Finally, intradermal route turned out to demonstrate the most safe and effective profile for immunization with both examined Vaccinia virus strains.S. N. ShchelkunovA. A. SergeevA. S. KabanovS. N. YakubitskyiT. V. BauerS. A. PyankovSankt-Peterburg : NIIÈM imeni Pasteraarticlevaccinia virusattenuationinfectionpathogenicityimmune responseantibodiesInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 11, Iss 2, Pp 357-364 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	vaccinia virus attenuation infection pathogenicity immune response antibodies Infectious and parasitic diseases RC109-216
spellingShingle	vaccinia virus attenuation infection pathogenicity immune response antibodies Infectious and parasitic diseases RC109-216 S. N. Shchelkunov A. A. Sergeev A. S. Kabanov S. N. Yakubitskyi T. V. Bauer S. A. Pyankov Route-coupled pathogenicity and immunogenicity of vaccinia virus variant inoculated mice
description	Vaccinia virus had played a key role in the global smallpox eradication. However, in case of mass vaccination with various Vaccinia virus strains severe side effects were revealed sometimes ending up with lethal outcomes, especially in immunocompromised humans. Hence, in 1980 the World Health Organization recommended to cancel smallpox vaccination after declaring about smallpox eradication. Over the last 40 years, human population virtually lost immunity not only against smallpox, but also against other zoonotic orthopoxvirus infections, such as monkeypox, cowpox, buffalopox, and camelpox. All of them pose a represent increasing threat to human health and heighten a risk of emerging highly contagious viruses due to natural evolution of previous zoonotic orthopoxviruses. In order to prevent development of small outbreaks into spreading epidemics and, thus, to decrease a risk of emergence due to natural evolution of highly pathogenic for humans orthopoxviruses, efforts should be applied to develop safe new generation live vaccines based on Vaccinia virus with target virulence genes inactivation. These strains should be examined in laboratory animal models inoculated via different routes. Currently, Vaccinia virus often becomes attenuated to create live recombinant vaccines due to inserting target DNA sequences into the virus virulence genes resulting in their inactivation. Vaccinia virus strain LIVP used in the Russian Federation as smallpox vaccine as well as derivative attenuated variant LIVP-GFP created by using genetic engineering methods with inactivating its thymidine kinase gene were examined. Such viruses were intracerebrally inoculated into suckling mice at doses of 101 or 102 PFU/animal for neurovirulence assessment. Adult mice were infected intranasally, subcutaneously or intradermally at doses of 107 or 108 PFU/animal and clinical manifestations were analyzed for 14 days. On the 28th day after the onset, blood serum samples were collected from individual mice to measure virus specific antibody level by using ELISA. It was shown that recombinant Vaccinia virus strain LIVP-GFP displayed markedly lowered neurovirulence and pathogenicity for mice as compared to parental LIVP. Finally, intradermal route turned out to demonstrate the most safe and effective profile for immunization with both examined Vaccinia virus strains.
format	article
author	S. N. Shchelkunov A. A. Sergeev A. S. Kabanov S. N. Yakubitskyi T. V. Bauer S. A. Pyankov
author_facet	S. N. Shchelkunov A. A. Sergeev A. S. Kabanov S. N. Yakubitskyi T. V. Bauer S. A. Pyankov
author_sort	S. N. Shchelkunov
title	Route-coupled pathogenicity and immunogenicity of vaccinia virus variant inoculated mice
title_short	Route-coupled pathogenicity and immunogenicity of vaccinia virus variant inoculated mice
title_full	Route-coupled pathogenicity and immunogenicity of vaccinia virus variant inoculated mice
title_fullStr	Route-coupled pathogenicity and immunogenicity of vaccinia virus variant inoculated mice
title_full_unstemmed	Route-coupled pathogenicity and immunogenicity of vaccinia virus variant inoculated mice
title_sort	route-coupled pathogenicity and immunogenicity of vaccinia virus variant inoculated mice
publisher	Sankt-Peterburg : NIIÈM imeni Pastera
publishDate	2021
url	https://doaj.org/article/5661108ca47949eabc4a92db7f760dab
work_keys_str_mv	AT snshchelkunov routecoupledpathogenicityandimmunogenicityofvacciniavirusvariantinoculatedmice AT aasergeev routecoupledpathogenicityandimmunogenicityofvacciniavirusvariantinoculatedmice AT askabanov routecoupledpathogenicityandimmunogenicityofvacciniavirusvariantinoculatedmice AT snyakubitskyi routecoupledpathogenicityandimmunogenicityofvacciniavirusvariantinoculatedmice AT tvbauer routecoupledpathogenicityandimmunogenicityofvacciniavirusvariantinoculatedmice AT sapyankov routecoupledpathogenicityandimmunogenicityofvacciniavirusvariantinoculatedmice
_version_	1718417917429678080

Route-coupled pathogenicity and immunogenicity of vaccinia virus variant inoculated mice

Ejemplares similares